Drugs / MY-586
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06127498 | May 2022 → Dec 2023 | COVID-19 | The Second Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
| — | NCT05977101 | Dec 2021 → Dec 2023 | Orthocoronavirinae infectious disease | The Second Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MY-586 | “MY-586 and MY-558, two active components of the novel coronavirus neutralizing antibody A8G6, were screened from peripheral blood lymphocytes of patients recovering from...” NCT06127498 ↗ |
| Action | Inhibit | “The novel coronavirus neutralizing antibody can directly bind to the envelope of the novel coronavirus to rapidly block the virus infection” NCT05977101 ↗ |
| Modality | Protein / enzyme biologic | “MY-586, a SARS-CoV-2 Neutralizing Antibody, was screened from peripheral blood lymphocytes of patients recovering from COVID-19” NCT05977101 ↗ |
| Route | Intranasal | “MY-586 SARS-CoV-2 Neutralizing Antibody is administered by nasal spray.” NCT05977101 ↗ |